SBIR reauthorization
This article was originally published in The Gray Sheet
Executive Summary
Medical device and other firms seeking Small Business Innovation Research program grant money could be majority-owned by venture capital outfits under the SBIR/STTR Reauthorization Act (S. 3362) approved by the Senate Committee on Small Business and Entrepreneurship July 30. A similar measure was passed by the full House on April 23 ("1The Gray Sheet," April 28, 2008, p. 13). Industry has complained that restrictions on SBIR grants for VC-funded firms have limited the utility of the government program that helps jump-start small company research. The Senate bill would allow no more than 18% of National Institutes of Health SBIR funds to go to firms that are majority owned by venture capitalists
You may also be interested in...
House Passes SBIR Reauthorization, Loosens Venture Capital Restrictions
A bill reauthorizing the Small Business Innovation Research (SBIR) program passed the House April 23. It would allow larger federal research and development grants to small companies and give the firms more flexibility in seeking funds from both federal agencies and venture capitalists
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.